| Biomarker ID | 282 |
| PMID | 18543251 |
| Year | 2008 |
| Biomarker | Golgi phosphoprotein 2 (GOLPH2) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-TGF-beta regulation of extracellular matrix |
| Experiment | prostate cancer Vs normal prostate epithelium |
| Type of Biomarker | Diagnostic |
| Cohort | A tissue microarray (TMA) containing 320 paired normal and prostate cancer TMA spots from 40 patients |
| Senstivity | 8190% |
| Specificity | 7560% |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Immunohistochemical |
| Clinical | No |
| Remarks | Molecular alterations associated with the Golgi apparatus may take place during prostate carcinogenesis. |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | GOLM1 |